Diabetes Care 39:12411249 Kazierad DJ, Bergman A, Tan B et al (2016) Effects of multiple ascending doses of the glucagon receptor antagonist PF-06291874 in patients with type 2 diabetes mellitus
After treatment with a complete medium containing LAbs@Lip@Rapa, Lip@BMn/Rapa, and LAbs@Lip@BMn/Rapa for 12 h, nonmigrated BV2 cells on the upper side of the membrane were gently removed using a cotton swab
Tirzepatide may cause slightly more gastrointestinal side effects due to dual-pathway activation, though most patients tolerate both well
Although Kesimpta (ofatumumab) has a new warning about liver injury, some studies have shown that the risk of liver injury is lower than with ocrelizumab
The following results were obtained: 1) cognitive function: mean difference (MD) = 2.16, 95% confidence interval (95% CI): 1.452.88
This meant exendin-4 could stay active in the body for much, much longer